Amivantamab plus lazertinib improved progression-free survival vs osimertinib as frontline therapy in patients with high-risk, EGFR-mutant advanced NSCLC.
Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.
Subcutaneous injection offers the potential for a faster, more convenient alternative to intravenous infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces.
Roche announced today that the European Commission has granted marketing authorization for Tecentriq SC, a cancer immunotherapy administered via subcutaneous injection. By 2023, over 38,000 patients.